The Trump administration is pulling the plug on a temporary Medicare subsidy that has been quietly propping up prescription drug plan premiums, a move that could leave some seniors paying more as soon as next year.
The target is a voluntary premium-stabilization demonstration that poured federal dollars into Medicare Part D plans after recent benefit changes shifted more costs onto insurers. For many enrollees the shift may show up as only a few extra bucks a month, but for others the hit could be far more noticeable when they shop for coverage during fall open enrollment.
According to the Wall Street Journal, the administration will not renew the program beyond 2026. Reuters reports that officials argue the temporary subsidies did what they were supposed to do by smoothing out wild premium swings, so they are no longer needed. Those officials also contend that the extra federal funding may have given insurers room to hike premiums in the first place.
How Big the Federal Backup Was
The Government Accountability Office found that the premium-stabilization demonstration cost roughly $9.8 billion over 2025–26, with about $6.2 billion spent in 2025 and $3.6 billion in 2026. The money was meant to blunt outsized premium jumps after statutory changes shifted more drug-cost risk to plan sponsors. GAO said the subsidies helped prevent the steep increases that might otherwise have slammed enrollees in stand-alone Part D plans.
Who Would Be Hit and How Much
About 56 million people were enrolled in Medicare Part D in early 2026, and roughly 24.9 million of them were in stand-alone prescription drug plans, according to KFF.
According to the Wall Street Journal, administration estimates suggest roughly 30% of beneficiaries would see monthly premium increases of less than $10, while about a quarter could see premiums stay the same or even drop. The rest will depend on how individual plans are structured, which drugs people take and whether insurers decide to eat some of the extra cost or simply pass it through to enrollees.
Reactions From Experts
Policy analysts warn that yanking this federal backstop could widen the edge Medicare Advantage plans already enjoy from larger rebate streams, leaving stand-alone drug plans with fewer rock-bottom premium options.
KFF Health News notes that the stabilization payments helped keep average stand-alone premiums from spiking this year. With that cushion going away, experts say Part D beneficiaries should be ready to comparison-shop aggressively during open enrollment instead of letting plans auto-renew in the background.
Consumer advocates add that the change makes this fall’s pricing season especially critical for people who rely on high-cost medications, since even a modest premium bump can sting when you are already juggling steep drug copays.
Timing and What to Watch
Insurers will submit their 2027 Part D bids in the fall, and beneficiaries will see the real-world premium numbers during Medicare’s open enrollment period, which begins Oct. 15, according to Medicare.gov.
Observers suggest keeping a close eye on plan notices, premium tables and any changes to formularies or pharmacy networks that might signal whether your insurer is absorbing the loss of federal support or shifting it onto you. If your prescriptions are expensive or you rely on a narrow pharmacy network, experts recommend combing through plan details once bids are posted instead of waiting for a nasty surprise in January.
For now, the administration insists the temporary program did its job and can bow out gracefully. Advocates counter that ending it strips away a national cushion for seniors at a time of major Part D upheaval. Expect more pointed commentary, and plenty of fine print from insurers, as the next enrollment season approaches.
